Key result
Vigabatrin at therapeutic (3.0 g) and supratherapeutic (6.0 g) doses did not prolong the QTc interval, with all 1-sided upper 95% CIs for the difference from placebo being <10 ms.
Why the study?
Does vigabatrin prolong the QTc interval in healthy participants?
RCT
Double-blind
4-sequence crossover
No
Does vigabatrin prolong the QTc interval in healthy participants?
Vigabatrin at therapeutic and supratherapeutic doses does not prolong the QTc interval in healthy volunteers, confirming a lack of proarrhythmic potential.
No takes yet. Share an insight, caveat, or question.
Vigabatrin shows no QTc prolongation; confirms cardiac safety and supports unrestricted clinical use in epilepsy without arrhythmia monitoring.
Tolbert et al. (2017) conducted an RCT in Healthy volunteers. Vigabatrin vs. Placebo and moxifloxacin was evaluated on Mean changes from baseline in placebo-corrected QTcF, QTcB, and QTcI. Vigabatrin at therapeutic (3.0 g) and supratherapeutic (6.0 g) doses did not prolong the QTc interval, with all 1-sided upper 95% CIs for the difference from placebo being <10 ms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: